In syngeneic mouse models (MOC1 and TC-1; mouse oral cancer), daily oral administration of these statins improved tumor control and survival when combined with PD-1 blockade, with lovastatin achieving MOC1 tumor rejection in 30% of cases. This evidence concerns the gene PDCD1 and neoplasm.